RBC puts Santarus at outperform, speculative risk

Santarus, Inc. was rated at outperform, speculative risk, and kept at its $10 price target by RBC Capital Markets analyst Douglas Miehm. The company reported a better-than-expected third-quarter loss of $0.26 per share, versus a loss of $0.40 per share in the prior-year period. Santarus' revenues beat RBC's estimates ($12.9 million compared to $12.0 million). Shares of the San Diego-based pharmaceutical company were up 23 cents, or 2.91%, at $7.98. (Nasdaq: SNTS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.